With Three New Videos, ICAP Helps Promote the Benefits of PrEP in Central America

Nov 23, 2022 | Stories from the Field

Pre-exposure prophylaxis – or PrEP – has proved to be a game-changer in helping reduce the transmission of HIV in countries around the world. As it continues to support the introduction of PrEP among vulnerable populations in regions where HIV is epidemic, ICAP at...

ICAP Grand Rounds Webinar — Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls

Oct 31, 2022 | Events, Webinars

Landmark Studies Supported by ICAP Contribute to FDA Approval of Injection for HIV Prevention

Aug 29, 2022 | News

For the first time, the U.S. Food and Drug Administration (FDA) has approved a long-acting injectable agent for the prevention of HIV, an alternative to daily pills for HIV prevention and an important step forward in the quest for global HIV epidemic control. ICAP at...

ICAP in Tanzania Celebrates the Lifesaving “Reach” of its Innovative FIKIA Project

Mar 28, 2022 | News

From 2016 to 2021, a project designed and supported by ICAP at Columbia University delivered critical HIV health services to key and vulnerable populations in Tanzania. Known as FIKIA – “to reach” in Kiswahili – the project brought HIV testing, prevention, and care to...

With ICAP’s Support, PrEP is Introduced to Central America

Mar 25, 2022 | News

ICAP at Columbia University is supporting the introduction of an important new tool to reduce HIV transmission in Guatemala and Panama. For the first time, people at risk for HIV in these Central American countries will have access to pre-exposure prophylaxis (PrEP),...

PrEP - pre-exposure prophylaxis